A review of the effect of atypical antipsychotics on weight

Psychoneuroendocrinology

Volumn 28, Issue SUPPL. 1, 2003, Pages 83-96

  Nasrallah, H ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

Atypical antipsychotics; Long term therapy; Schizophrenia; Weight gain

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; HISTAMINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN; ZIPRASIDONE;

ADRENERGIC SYSTEM; ALGORITHM; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FOLLOW UP; HUMAN; LONG TERM CARE; NEUROLOGICAL COMPLICATION; OBESITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SIDE EFFECT; WEIGHT GAIN;

EID: 0037214218     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4530(02)00114-2     Document Type: Review

References (57)

1. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., Weiden P.J. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry. 156:1999a;1686-1696.
2. Allison D.B., Fontaine K.R., Heo M., Mentore J.L., Cappelleri J.C., Chandler L.P., Weiden P.J., Cheskin L.J. The distribution of body mass index among individuals with and without schizophrenia. J. Clin. Psychiatry. 60:1999b;215-220.
3. Anderson C., Clark W.R., True J., Ereshefsky L., Miller A. Risperidone, a novel antipsychotic, and weight change. Pharmacotherapy. 13:1993;292.
4. Arato M., O'Connor R., Bradbury J.E., Meltzer H. Ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia. Schizophr. Res. 36:1999;270.
5. Arvanitis L.A., Miller B.G. Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol. Psychiatry. 42:1997;233-246.
6. Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr. Scand. 100:1999;3-16.
7. Beasley C.M. Safety of olanzapine. J. Clin. Psychiatry Monograph. 15:1997;19-21.
8. Bernstein J.G. Induction of obesity by psychotropic drugs. Ann. N. Y. Acad. Sci. 499:1987;203-215.
9. Brecher M., Geller W. Weight gain with risperidone. J. Clin. Psychopharmacol. 17:1997;435-436.
10. Brecher M., Melvin K. Effect of long-term quetiapine monotherapy on weight in schizophrenia (poster). Presented at the American Psychiatric Association Annual Meeting, New Orleans, Louisiana, USA. 2001.
11. Brecher M., Rak I.W., Westhead E.K., Jones A.M. The long-term effect of quetiapine ('Seroquel') monotherapy on weight in patients with schizophrenia. Int. J. Psych. Clin. Pract. 4:2000;287-292.
12. Brömel T., Blum W.F., Ziegler A., Schulz E., Bender M., Fleischhaker C., Remschmidt H., Krieg J.C., Hebebrand J. Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol. Psychiatry. 3:1998;76-80.
13. Cassidy F., Ahearn E., Carroll B.J. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am. J. Psychiatry. 156:1999;1417-1420.
14. Claus A., Bollen J., De Cuyper H., Eneman M., Malfroid M., Peuskens J., Heylen S. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr. Scand. 85:1992;295-305.
15. Cohen S., Chiles J., MacNaughton A. Weight gain associated with clozapine. Am. J. Psychiatry. 147:1990;503-504.
16. Csernansky J.G., Mahmoud R., Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N. Engl. J. Med. 346:2002;16-22.
17. Daniel D.G., Zimbroff D.L., Potkin S.G., Reeves K.R., Harrigan E.P., Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology. 20:1999;491-505.
18. Davies A., Adena M.A., Keks N.A., Catts S.V., Lambert T., Schweitzer I. Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety. Clin. Ther. 20:1998;58-71.
19. Fenton W.S., Blyler C.F., Heinssen R.K. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr. Bull. 23:1997;637-651.
20. Frankenburg F.R., Zanarini M.C., Kando J., Centorrino F. Clozapine and body mass change. Biol. Psychiatry. 43:1998;520-524.
21. Geodon (ziprasidone HCI) Prescribing Information, 2001. Pfizer. Available at: www.pfizer.com/hml/pi's/geodonpi.pdf .
22. Glassman A.H., Bigger J.T. Jr. Antipsychotic drugs: prolonged QTc interval, torsades de pointes, and sudden death. Am. J. Psychiatry. 158:2001;1774-1782.
23. Goldstein L.E., Sporn J., Brown S.E., Kim H., Finkelstein J., Gaffey G.K., Sachs G., Stern T.A. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics. 40:1999;438-443.
24. Hellewell J.S.E., Kalali A.H., Langham S.J., McKellar J., Awad A.G. Patient satisfaction and acceptability of long-term treatment with quetiapine. Int. J. Psych. Clin. Pract. 3:1999;105-113.
25. Henderson D.C. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs. 16:2002;77-89.
26. Javitt D.C. Treatment of negative and cognitive symptoms. Curr. Psychiatry Rep. 1:1999;25-30.
27. Jibson M.D., Tandon R. New atypical antipsychotic medications. J. Psychiatr. Res. 32:1998;215-228.
28. Jones A.M., Rak I.W., Raniwalla J., Phung D., Melvin K. Weight changes in patients treated with 'Seroquel' (quetiapine) (poster). Presented at the Winter Workshop, February 5-11, Davos, Switzerland. 2000.
29. Koval M.S., Rames L.J., Christie S. Diabetic ketoacidosis associated with clozapine treatment. Am. J. Psychiatry. 151:1994;1520-1521.
30. Kraus T., Haack M., Schuld A., Hinze-Selch D., Kühn M., Uhr M., Pollmächer T. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am. J. Psychiatry. 156:1999;312-314.
31. Lamberti J.S., Bellnier T., Schwarzkopf S.B. Weight gain among schizophrenic patients treated with clozapine. Am. J. Psychiatry. 149:1992;689-690.
32. Leadbetter R., Shutty M., Pavalonis D., Vieweg V., Higgins P., Downs M. Clozapine-induced weight gain: prevalence and clinical relevance. Am. J. Psychiatry. 149:1992;68-72.
33. Melkersson K.I., Hulting A.L., Brismar K.E. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J. Clin. Psychiatry. 61:2000;742-749.
34. Mukherjee S., Decina P., Bocola V., Saraceni F., Scapicchio P.L. Diabetes mellitus in schizophrenic patients. Compr. Psychiatry. 37:1996;68-73.
35. Nasrallah H. High prevalence of diabetes mellitus in schizophrenia, schizoaffective disorder, and bipolar disorder. Int. J. Neuropsychopharmacology. 3:(Suppl. 1):2000;S116. (abstract P.01.096).
36. Nemeroff C.B. Dosing the antipsychotic medication olanzapine. J. Clin. Psychiatry. 58:(Suppl. 10):1997;45-49.
37. Newcomer J.W., Haupt D.W., Fucetola R., Melson A.K., Schweiger J.A., Cooper B.P., Selke G. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch. Gen. Psychiatry. 59:2002;337-345.
38. Owens D.G. Extrapyramidal side effects and tolerability of risperidone: a review. J. Clin. Psychiatry. 55:(Suppl.):1994;29-35.
39. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br. J. Psychiatry. 166:1995;712-726. (discussion 727-733).
40. Popli A.P., Konicki P.E., Jurjus G.J., Fuller M.A., Jaskiw G.E. Clozapine and associated diabetes mellitus. J. Clin. Psychiatry. 58:1997;108-111.
41. Purdon S.E., Malla A., Labelle A., Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J. Psychiatry Neurosci. 26:2001;137-149.
42. Rak I.W., Jones A.M., Raniwalla J., Phung D., Melvin K. Weight changes in patients treated with Seroquel (quetiapine). Schizophr. Res. 41:2000;206. (abstract B83).
43. Reinstein M.J., Sirotovskaya L.A., Jones L.E., Mohan S., Chasanov M.A. Effect of clozapine-quetiapine combination therapy on weight and glycaemic control. Preliminary findings. Clin. Drug Invest. 18:1999;99-104.
44. Sheitman B.B., Bird P.M., Binz W., Akinli L., Sanchez C. Olanzapine-induced elevation of plasma triglyceride levels. Am. J. Psychiatry. 156:1999;1471-1472.
45. Shelton R.C., Tollefson G.D., Tohen M., Stahl S., Gannon K.S., Jacobs T.G., Busas W.R., Bymaster F.P., Zhang W., Spencer K.A., Feldman P.D., Meltzer H.Y. A novel augmentation strategy for treating resistant major depression. Am. J. Psychiatry. 158:2001;131-134.
46. Simpson G.M., O'Sullivan M.D., Siu C. Ziprasidone versus olanzapine in schizophrenia: results of a double-blind trail. Presented at the American Psychiatric Association Annual Meeting, New Orleans, Louisiana, USA (abstract NR252). 2001.
47. Spohn H.E., Strauss M.E. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J. Abnorm. Psychol. 98:1989;367-380.
48. Stanton J.M. Weight gain associated with neuroleptic medication: a review. Schizophr. Bull. 21:1995;463-472.
49. Sussman N. Introduction: weight gain and glucose regulation during antipsychotic drug treatment. J. Clin. Psychiatry. 62:(Suppl. 23):2001;3-4.
50. Sussman N., Ginsberg D. Effects of psychotropic drugs on weight. Psychiatr. Ann. 29:1999;580-594.
51. Tran P.V., Dellva M.A., Tollefson G.D., Beasley C.M. Jr., Potvin J.H., Kiesler G.M. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J. Clin. Psychiatry. 58:1997;205-211.
52. Turrone P., Kapur S., Seeman M.V., Flint A.J. Elevation of prolactin levels by atypical antipsychotics. Am. J. Psychiatry. 159:2002;133-135.
53. Umbricht D.S., Pollack S., Kane J.M. Clozapine and weight gain. J. Clin. Psychiatry. 55:(Suppl. B):1994;157-160.
54. Weiden P., Aquila R., Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J. Clin. Psychiatry. 57:(Suppl. 11):1996;53-60.
55. Weinsier R.L., Hunter G.R., Heini A.F., Goran M.I., Sell S.M. The etiology of obesity: relative contribution of metabolic factors, diet, and physical activity. Am. J. Med. 105:1998;145-150.
56. WHO, 1998. http://www.who.int/dsa/cat98/nut8.htm# Obesity: Preventing and Managing the Global Epidemic.
57. Wirshing D.A., Wirshing W.C., Kysar L., Berisford M.A., Goldstein D., Pashdag J., Mintz J., Marder S.R. Novel antipsychotics: comparison of weight gain liabilities. J. Clin. Psychiatry. 60:1999;358-363.